STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

Liknande verk

• STAT1-Induced HLA class I Upregulation Enhances Immunogenicity and Clinical Response to anti-EGFR mAb Cetuximab Therapy in HNC Patients
  av: Srivastava, Raghvendra M., et al.
  Publicerad: (2015)
• EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
  av: Concha-Benavente, Fernando, et al.
  Publicerad: (2013)
• SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells
  av: Leibowitz, Michael S., et al.
  Publicerad: (2013)
• Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
  av: Kansy, Benjamin A, et al.
  Publicerad: (2015)
• CTLA-4(+) Regulatory T Cells Increased in Cetuximab Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
  av: Jie, Hyun-Bae, et al.
  Publicerad: (2015)